Biology

FOXO Technologies Appoints Erin Sharoni to Chief Product Officer of FOXO LIFE

Tuesday, July 27, 2021 - 1:00pm

MINNEAPOLIS, July 27, 2021 /PRNewswire/ -- FOXO Technologies Inc. ("FOXO"), a leader in commercializing epigenetic biomarkers of health and aging today announced the appointment of Erin Sharoni to the role of Chief Product Officer.

Key Points: 
  • MINNEAPOLIS, July 27, 2021 /PRNewswire/ -- FOXO Technologies Inc. ("FOXO"), a leader in commercializing epigenetic biomarkers of health and aging today announced the appointment of Erin Sharoni to the role of Chief Product Officer.
  • In this newly created executive role, Sharoni will lead the development and launch of FOXO LIFE, the first life insurance company to be powered by molecular health technology.
  • In her role as Chief Product Officer, Sharoni will oversee all aspects of marketing, sales, and product operations.
  • "Erin Sharoni brings incredible expertise and experience to lead FOXO LIFE and its expanded promise of helping its customers live an optimized, healthy life," says Jon Sabes, CEO and Founder of FOXO.

DGAP-News: CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

Tuesday, July 27, 2021 - 1:07pm

CEVEC also announced that the ELEVECTA(R) Technology is currently being implemented in HEK293 as a second host cell type.

Key Points: 
  • CEVEC also announced that the ELEVECTA(R) Technology is currently being implemented in HEK293 as a second host cell type.
  • As HEK293 is the most widely used host cell line in gene therapy manufacturing, CEVEC expects to see a significant increase in demand from clients and partners.
  • "We are delighted to be part of this financing round with the aim of accelerating the company's growth and becoming market leader for stable vector manufacturing technologies in cell and gene therapies."
  • The company's product portfolio comprises platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins.

Talis Biomedical to Announce Second Quarter 2021 Financial Results on August 10, 2021

Tuesday, July 27, 2021 - 1:00pm

MENLO PARK, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter after market close on Tuesday, August 10, 2021.

Key Points: 
  • MENLO PARK, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter after market close on Tuesday, August 10, 2021.
  • Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results.
  • A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedicals website at www.talis.bio .
  • The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress

Tuesday, July 27, 2021 - 1:00pm

isolates collected in Asia-Pacific countries, in two presentations at the International Society for Human and Animal Mycology (ISHAM) Asia Congress taking place virtually from August 6-8, 2021.

Key Points: 
  • isolates collected in Asia-Pacific countries, in two presentations at the International Society for Human and Animal Mycology (ISHAM) Asia Congress taking place virtually from August 6-8, 2021.
  • Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections incriticallyill patients.
  • ISHAM Asia is a new conference aiming to increase opportunities for regional healthcare professionals and researchers and encourages their participation to interact with global leaders in the field of medical mycology.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Tuesday, July 27, 2021 - 12:00pm

Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).

Key Points: 
  • Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).
  • A single infusion in the treatment group consists of 200 million stem cells, or approximately 1.2 billion stem cells per patient over the course of study.
  • HBSCRF remains the only organization globally to administer pure, fresh mesenchymal stem cells, an adult stem cell harvested from fat, in such high quantities over repeat treatments.
  • Clinical trial authorizations encompass COVID-19 prevention and treatment , traumatic brain injury , Parkinsons disease , and multiple sclerosis.

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

Tuesday, July 27, 2021 - 11:30am

PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolves all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world, and dismissing all infringement claims with prejudice.

Key Points: 
  • The agreement grants each company a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single cell analysis.
  • Todays settlement underscores the value of our innovation and strong patent portfolios built over the last nine years, said Eric Whitaker, General Counsel of 10x Genomics.
  • 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health.
  • These forward-looking statements include statements regarding 10x Genomics product performance, configuration and capabilities and adoption and the global cross license agreement between 10x Genomics and Bio-Rad Laboratories.

Olink: CORAL to use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases

Tuesday, July 27, 2021 - 12:00pm

UPPSALA, Sweden, July 27, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Olink) (Nasdaq: OLK) today announced that CORAL, a new collaborative community of scientists, will use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases.

Key Points: 
  • UPPSALA, Sweden, July 27, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Olink) (Nasdaq: OLK) today announced that CORAL, a new collaborative community of scientists, will use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases.
  • CORAL is a new collaborative community of scientists that work on diverse neurological conditions studying blood and cerebrospinal fluid (CSF) on the Olink Proteomics platform to identify novel biomarkers and biological mechanisms for neurological diseases.
  • CORAL is a collaborative community of scientists that work on diverse neurological conditions studying blood and CSF to identify novel biomarkers and biological mechanisms for neurological diseases.
  • The purpose of CORAL is to accelerate the development of biomarkers and mechanisms for neurological diseases, starting from array-based proteomics up to validation and implementation in the clinic.

iOnctura Project Evaluating Novel PI3Kδ-inhibitor IOA-244 in Lymphoma to be Co-funded by Innosuisse

Tuesday, July 27, 2021 - 8:00am

The research project, scheduled to start in August 2021, will run alongside iOncturas expanding clinical program for IOA-244, focussed on the treatment of solid tumors (NCT04328844).

Key Points: 
  • The research project, scheduled to start in August 2021, will run alongside iOncturas expanding clinical program for IOA-244, focussed on the treatment of solid tumors (NCT04328844).
  • Amongst other aspects, the new project will explore patient stratification biomarkers, combination interventions to increase treatment response rates in lymphoma and methods for minimizing potential resistance pathways.
  • I am delighted iOnctura will be able to draw on the experience of Francesco Bertoni and his group to better understand the mechanisms of resistance in lymphoma.
  • Project funding comes from Innosuisse, the Swiss national Innovation Agency which has a remit to promote science-based innovation to increase the competitiveness of small and medium-sized enterprises in Switzerland.

Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021

Tuesday, July 27, 2021 - 1:00am

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).
  • Several of these relationships were not apparent in ENGAGE, in which a clinical treatment effect of aducanumab was not observed.

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

Monday, July 26, 2021 - 9:10pm

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • Leveraging the experience gained from the development and marketing of a treatment for Alzheimers disease, Eisai aims to establish the Eisai Dementia Platform.
  • Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.